After a couple of misfires, Pfizer has finally won FDA approval for its biosimilar of anemia drug Epogen/Procrit, a drug whose U.S. sales generated about $1.8 billion last year for partners Amgen and ...
Please provide your email address to receive an email when new articles are posted on . The FDA today approved epoetin alfa-epbx, the first epoetin alfa biosimilar, for the treatment of anemia caused ...
Retacrit will be priced 57.1% below the Wholesale Acquisition Cost (WAC) of Procrit and 33.5% below the WAC of Epogen, at $11.03 per 1000 Units/mL. In addition, Retacrit is indicated for the reduction ...
The FDA has approved Pfizer’s epoetin alfa-epbx (Retacrit), a biosimilar to epoetin alfa (Epogen), marking the first biosimilar approval of 2018 and the first biosimilar erythropoiesis-stimulating ...
The US Food and Drug Administration (FDA) has approved the first biosimilar erythropoiesis-stimulating agent. The reference product is epoetin alfa (Epogen/Procrit, Amgen). The new biosimilar is ...
Sales of Amgen Inc.’s best-selling drug Epogen would fall if a new Medicare policy, released in draft form Thursday, went into effect, an agency official said. The proposal called for stricter review ...
Dec. 2, 2005 -- The US Food and Drug Administration (FDA), Amgen Inc, and Ortho Biotech Clinical Affairs, LLC, have notified healthcare professionals via letter regarding revisions to the safety ...
(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO) ...
Please provide your email address to receive an email when new articles are posted on . The FDA's approval this week of Affymax's new ESA peginesatide will bring competition to the anemia treatment ...
Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. Two thousand three hundred seventy patients with nonmyeloid malignancies who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results